Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
25
Ṁ11052030
77%
chance
1D
1W
1M
ALL
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy. Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein). The gene therapy must be for humans.
Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
Get Ṁ1,000 play money
Related questions
Related questions
By 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
17% chance
Will there be an in-vivo gene therapy that edits multiple genes at once approved anywhere in the world before 2030?
52% chance
Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
The FDA will approve an AI developed cure before the end of the decade (<2030) for a previously incurable major illness.
56% chance
Will there be an FDA-approved age reversal treatment based on partial cell reprogramming by 2030?
32% chance
Will we have gene therapy for a major strain of Crohn's disease by 2030?
26% chance
Will a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
59% chance
Will I receive any kind of gene therapy created using CRISPR before I die?
59% chance
Will we be able to edit our own genomes by 2050?
64% chance
Will there be a CRISPR treatment for Ehlers-Danlos Syndromes before 2040?
52% chance